Cytarabine - Warnings and Precautions
The following warnings and precautions are taken directly from the US FDA-approved drug label for Cytarabine. This is the same information dispensing pharmacists read.
\u26a0\ufe0f Boxed Warning (Highest FDA Alert)
WARNING Only physicians experienced in cancer chemotherapy should use Cytarabine Injection. For induction therapy patients should be treated in a facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The main toxic effect of cytarabine is bone marrow suppression with leukopenia, thrombocytopenia and anemia. Less serious toxicity includes nausea, vomiting, diarrhea and abdominal pain, oral ulceration and hepatic dysfunction. The physician must judge possible benefit to the patient against known toxic effects of this drug in considering the advisability of therapy with cytarabine. Before making this judgment or beginning treatment, the physician should be familiar with the following text.
WARNINGS ( see boxed WARNING ) Cytarabine is a potent bone marrow suppressant.
Therapy should be started cautiously in patients with pre-existing drug-induced bone marrow suppression.
Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leukocyte and platelet counts performed daily.
Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.
Facilities should be available for management of complications, possibly fatal, of bone marrow suppression (infection resulting from granulocytopenia and other impaired body defenses and hemorrhage secondary to thrombocytopenia).
One case of anaphylaxis that resulted in acute cardiopulmonary arrest and required resuscitation has been reported.
This occurred immediately after the intravenous administration of cytarabine.
Severe and at times fatal CNS, GI and pulmonary toxicity (different from that seen with conventional therapy regimens of cytarabine) has been reported following some of the experimental cytarabine dose schedules.
These reactions include reversible corneal toxicity, and hemorrhagic conjunctivitis, which may be prevented or diminished by prophylaxis with a local corticosteroid eye drop; cerebral and cerebellar dysfunction including personality changes, somnolence and coma, usually reversible; severe gastrointestinal ulceration, including pneumatosis cystoides intestinalis leading to peritonitis; sepsis and liver abscess; pulmonary edema, liver damage with increased hyperbilirubinemia, bowel necrosis; and necrotizing colitis.
Rarely, severe skin rash, leading to desquamation has been reported.
Complete alopecia is more commonly seen with experimental high dose therapy than with standard cytarabine treatment programs.
If experimental high dose therapy is used, do not use a Cytarabine Injection containing benzyl alcohol.
Cases of cardiomyopathy with subsequent death has been reported following experimental high dose therapy with cytarabine in combination with cyclophosphamide when used for bone marrow transplant preparation.
A syndrome of sudden respiratory distress, rapidly progressing to pulmonary edema and radiographically pronounced cardiomegaly has been reported following experimental high dose therapy with cytarabine used for the treatment of relapsed leukemia from one institution in 16/72 patients.
The outcome of this syndrome can be fatal.
Benzyl alcohol is contained in this product.
Benzyl alcohol has been reported to be associated with a fatal "Gasping Syndrome" in premature infants.
Two patients with childhood acute myelogenous leukemia who received intrathecal and intravenous cytarabine at conventional doses (in addition to a number of other concomitantly administered drugs) developed delayed progressive ascending paralysis resulting in death in one of the two patients.
DO NOT USE CYTARABINE INJECTION (which contains benzyl alcohol) INTRATHECALLY.
Use in Pregnancy: Cytarabine can cause fetal harm when administered to a pregnant woman.
Cytarabine causes abnormal cerebellar development in the neonatal hamster and is teratogenic to the rat fetus.
There are no adequate and well-controlled studies in pregnant women.
Women of childbearing potential should be advised to avoid becoming pregnant.
Applies to YOU?
Some warnings apply only to specific age groups, health conditions, or other medicines. Ask GoDavaii AI to filter which of these 23+ warnings apply to your profile.
Ask Health AI \u2192